Elavil withdrawal

Elavil Withdrawal

Head symptoms? Anxiety? Insomnia? Of course you do.

You likely would prefer to cut to the chase and find out what you can do to get relief quickly. Omega 3 Supreme TG has been formulated to help cut through the head symptoms quickly.

Neuro Day is formulated for the daytime anxiety and most other daytime side effects

Neuro Night for sleep and body aches

JNK Formula helps bring a gene back to balance the medication has altered.

Go to the manufacturers web site Click here and purchase JNK Formula, Neuro Day and Neuro Night and then get a couple bottles of the Omega 3 Supreme. You will be needing the extra omega's.

The web site you are on now, The Road Back, offers information on how to get off Elavil, prevent Elavil withdrawal side effects as well as eliminating current Elavil side effects.

You will find on this site the complete book, How to Get Off Psychoactive Drugs Safely. Click How to Start, located on the top navigation menu for book. Since 1999, over 50,000 people have now used this information to get off their antidepressant or other type of psychoactive medication.

Withdrawal off of Elavil does not have to be difficult and handling current Elavil side effects can be resolved quickly.

Note: If you are taking Elavil as well as an anti-anxiety medication (benzodiazepine), the anti-anxiety medication must be discontinued first. If you are only discontinuing the Elavil the Elavil must be reduced very slowly to prevent withdrawal side effects from the anti-anxiety drug. Elavil slows the metabolism rate of anti-anxiety drugs and when the Elavil is removed from the system the anti-anxiety medication will not take as long to metabolize and this creates a withdrawal effect from the anti-anxiety medication. See chapter 9 on the left side of each page for anti-anxiety medication procedures.

In May 2012, our program made its next leap forward and at this time; completely eliminating Elavil side effects is not only within our grasp, it is here.

Anxiety in the daytime, insomnia at night, the dreaded head symptoms common with Elavil withdrawal can now be a thing of the past.

There is quite a bit of information on our web site and if the ill effects from Elavil have you unable to read very much text, we can make this very quick and simple.

These supplements are manufactured and sold by Neuro Genetic Solutions.

Amitriptyline
Brand name (Elavil and Endep)

Pharmacology

Antidepressant

Indications

In the drug management of depressive illness.

Amitriptyline may be used in depressive illness of psychotic or endogenous nature and in selected patients with neurotic depression. Endogenous depression is more likely to be alleviated than are other depressive states. Amitriptyline, because of its sedative action, is also of value in alleviating the anxiety component of depression.

As with other tricyclic antidepressants, amitriptyline may precipitate hypomanic episodes in patients with bipolar depression. These drugs are not indicated in mild depressive states and depressive reactions.

Contraindications  

In patients who have shown prior hypersensitivity to it. It should not be given concomitantly with a MAO inhibiting compound. Hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and MAO inhibiting drugs simultaneously. When it is desired to substitute amitriptyline for a MAO inhibitor, a minimum of 14 days should be allowed to elapse after the latter is discontinued. Amitriptyline should then be initiated cautiously with gradual increase in dosage until optimum response is achieved.

This drug is not recommended for use during the acute recovery phase following myocardial infarction and in the presence of acute congestive heart failure.

See Pregnancy under Warnings.

Warnings  

Amitriptyline should be used with caution in patients with a history of seizures, impaired liver function, a history of hepatic damage or blood dyscrasias and, because of its atropine-like action, in patients with a history of urinary retention, or with narrow-angle glaucoma or increased intraocular pressure. In patients with narrow-angle glaucoma, even average doses may precipitate an attack.

There has been a report of fatal dysrhythmia occurring as late as 56 hours after amitriptyline overdose.

Patients with cardiovascular disorders should be watched closely. Tricyclic antidepressant drugs, including amitriptyline, particularly when given in high doses, have been reported to produce arrhythmias, sinus tachycardia, and prolongation of the conduction time.

A few instances of unexpected deaths have been reported in patients with cardiovascular disorders. Myocardial infarction and stroke have also been reported with drugs of this class. Therefore, these drugs should be used with caution in patients with a history of cardiovascular disease, such as myocardial infarction and congestive heart failure.

Concurrent administration of amitriptyline and electroshock therapy may increase the hazards of therapy. Such treatment should be limited to patients for whom it is essential.

Close supervision is required when amitriptyline is given to hyperthyroid patients or those receiving thyroid medication.

Occupational Hazards:  

May impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle.

Pregnancy:
There are no well-controlled studies in pregnant women; therefore, in administering the drug to pregnant patients or women who may become pregnant, the potential benefits must be weighed against the possible hazards to mother and child.

Lactation:
Amitriptyline is detectable in breast milk. Because of the potential for serious adverse reactions in infants from amitriptyline, a decision should be made whether to discontinue nursing or discontinue the drug.

Children:
In view of the lack of experience with the use of this drug in the treatment of depression in children, amitriptyline is not recommended for depressed patients under 12 years of age.

Precautions  

The potency of amitriptyline is such that addition of other antidepressant drugs generally does not result in any additional therapeutic benefit. Untoward reactions have been reported after the combined use of antidepressant agents having varying modes of activity. Accordingly, combined use of amitriptyline and other antidepressant drugs should be undertaken only with due recognition of the possibility of potentiation and with a thorough knowledge of the pharmacology of both drugs. There has been no reports of untoward events when patients receiving amitriptyline were changed immediately to protriptyline or vice versa.

When amitriptyline is used to treat the depressive component of schizophrenia, activation or aggravation of existing psychotic manifestation may occur. Likewise, manic depressive patients may experience hypomanic or manic episodes and hyperactive or agitated patients may become overstimulated. Paranoid delusions, with or without associated hostility, may be exaggerated. A reduction in dose or discontinuation of amitriptyline may be indicated and administration of a neuroleptic such as a phenothiazine, be considered under these circumstances.

Seriously depressed patients should be carefully supervised. The possibility of suicide in depressed patients remains during treatment. Patients should not have access to large quantities of this drug during treatment.

Discontinue the drug several days before elective surgery if possible.

Drug Interactions:  

Amitriptyline may block the antihypertensive action of guanethidine or similarly acting compounds.

When amitriptyline is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosage are required. Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs.

Since amitriptyline, in combination with anticholinergic type drugs, may give rise to paralytic ileus, particularly in elderly or hospitalized patients, appropriate measures should be taken if constipation occurs in these patients.

Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants.

Caution is advised if patients receive large doses of ethchlorvynol concurrently. Transient delirium has been reported in patients who were treated with 1 g of ethchlorvynol and 75 to 150 mg of amitriptyline.

Amitriptyline may enhance the response to alcohol and the effects of barbiturates and other CNS depressants. Delirium has been reported with concurrent administration of amitriptyline and disulfiram.

Note:
Included in this listing which follows are a few adverse reactions which have not been reported with this specific drug. However, pharmacological similarities among the tricyclic antidepressant drugs require that each of the reactions be considered when amitriptyline is administered.

Behavioral:
Drowsiness, fatigue, activation of latent schizophrenia, disorientation, confusional states, hallucinations, delusions, hypomanic reactions, disturbed concentration, nightmares, insomnia, restlessness, agitation, excitement, jitteriness, anxiety, giddiness.

Neurological:
Epileptiform seizures, coma, dizziness, tremors, numbness, tingling, paresthesias of the extremities, peripheral neuropathy, headache, ataxia, alteration in EEG patterns, extrapyramidal symptoms including abnormal involuntary movements and tardive dyskinesia, dysarthria, tinnitus, incoordination, and slurred speech.

Anticholinergic:
Urinary retention, dilatation of the urinary tract, constipation, paralytic ileus, especially in the elderly, hyperpyrexia, dry mouth, blurred vision, disturbance of accommodation, increased intraocular pressure, precipitation of latent glaucoma, aggravation of existing glaucoma, and mydriasis.

Cardiovascular:
Quinidine-like effect and other non-specific ECG changes and changes in AV conduction, prolonged conduction time, asystole, hypotension, syncope, hypertension, palpitation, arrhythmias, heart block, ventricular tachycardia, fibrillation, myocardial infarction, stroke, unexpected death in patients with cardiovascular disorders.

Hematologic:
Bone marrow depression, including agranulocytosis, leukopenia, eosinophilia, purpura, thrombocytopenia.

Allergic:
Skin rash, urticaria, photosensitization, edema of the face and tongue, itching.

Gastrointestinal:
Nausea, epigastric distress, heartburn, vomiting, hepatitis (including altered liver function and jaundice), anorexia, stomatitis, peculiar taste, diarrhea, parotid swelling, black tongue may occur.

Endocrine:
Testicular swelling, gynecomastia and impotence in the male, breast enlargement and galactorrhea in the female, increased or decreased libido, elevation and lowering of blood sugar levels, syndrome of inappropriate ADH (antidiuretic hormone) secretion.

Miscellaneous:
Weakness, increased perspiration, edema, urinary frequency, alopecia, increased appetite, weight gain, weight loss.

Withdrawal Symptoms:
Abrupt cessation of treatment after prolonged administration may produce nausea, headache, and malaise. Gradual dosage reduction has been reported to produce, within 2 weeks, transient symptoms including irritability, restlessness, and dream and sleep disturbance. These symptoms are not indicative of addiction. Rare instances have been reported of mania or hypomania occurring within 2 to 7 days following cessation of chronic therapy with tricyclic antidepressants.